LOXL2 silencing suppresses angiotensin II-induced cardiac hypertrophy through the EMT process and TGF-β1/Smad3/NF-κB pathway

Document Type : Original Article


Department of Cardiology, Shanghai University of Medicine & Health Sciences affiliated Zhoupu Hospital, Shanghai 201318, China


Objective(s): Atrial fibrillation (AF) is a common arrhythmia with atrial myocyte hypertrophy linked with stroke, heart failure, and increased mortality. Lysyl oxidase-like 2 (LOXL2) involves the cross-linking of collagen in the extracellular matrix (ECM). In the present study, we investigated the roles and underlying mechanisms of LOXL2 on cardiomyocyte hypertrophy. 
Materials and Methods: The expression of LOXL2 mRNA and protein were detected in angiotensin II (Ang II) treated rat cardiomyocytes H9c2 by RT-qPCR and western blot. Small interfering RNA (siRNA) mediated LOXL2 gene silencing was used to evaluate cardiac hypertrophy and related markers. Also, the protein expression of EMT markers and Smad3/NF-κB pathway was determined by western blot. 
Results: Ang II significantly increased mRNA and protein expressions of LOXL2 and increased mRNA levels of myocardial hypertrophy markers, including ANP, BNP, and β-MHC in H9c2 cells. Silencing of LOXL2 significantly suppressed Ang II-induced hypertrophy and reversed the increase in ANP, BNP, and β-MHC mRNA levels. Also, EMT markers’ expressions, as evidenced by increased E-cadherin and decreased vimentin, α-smooth muscle actin (α-SMA), fibroblast-specific protein (FSP), and collagen 1A1. Mechanistically, we found that LOXL2 silencing suppressed protein expressions of TGF-β1, p-Smad3, and p-NF-κB in Ang II-stimulated H9c2 cells. LOXL2 silencing also attenuated Ang II-induced increased expression and content of proinflammatory cytokines IL-1β (H) and TNF-α. 
Conclusion: Our data speculated that LOXL2 might be a potential contributing factor to Ang II-induced cardiac hypertrophy, and TGF-β1/Smad3/NF-κB is involved in a signal axis and might be a potential strategy in treating cardiac hypertrophy. 


1. Andrade J, Khairy P, Dobrev D, Nattel S. The clinical profile and pathophysiology of atrial fibrillation: Relationships among clinical features, epidemiology, and mechanisms. Circ Res 2014; 114: 1453-1468.
2. Nattel S. Molecular and cellular mechanisms of atrial fibrosis in atrial fibrillation. JACC Clin Electrophysiol 2017; 3: 425-435.
3. Nattel S, Harada M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J Am Coll Cardiol 2014; 63: 2335-2345.
4. Tzeis S, Asvestas D, Vardas P. Atrial fibrosis: Translational considerations for the management of AF patients. Arrhythm Electrophysiol Rev 2019; 8: 37-41.
5. Shimizu I and Minamino T. Physiological and pathological cardiac hypertrophy. J Mol Cell Cardiol 2016; 97: 245-262.
6. Cox EJ, Marsh SA. A systematic review of fetal genes as biomarkers of cardiac hypertrophy in rodent models of diabetes. PloS One 2014; 9:e92903.
7. Takimoto-Ohnishi E, Murakami K. Renin-angiotensin system research: from molecules to the whole body. J Physiol Sci 2019; 69: 581-587.
8. Pugliese NR, Masi S, Taddei S. The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure. Heart Fail Rev 2020; 25: 31-42.
9. Nair GM, Nery PB, Redpath CJ, Birnie DH. The Role of renin-angiotensin system in atrial fibrillation. J Atr Fibrillation 2014; 6: 972.
10. Moon HJ, Finney J, Ronnebaum T, Mure M. Human lysyl oxidase-like 2. Bioorg Chem 2014; 57: 231-241.
11. Kim YM, Kim EC, Kim Y. The human lysyl oxidase-like 2 protein functions as an amine oxidase toward collagen and elastin. Mol Biol Rep 2011; 38: 145-149.
12. Vallet SD, Ricard-Blum S. Lysyl oxidases: From enzyme activity to extracellular matrix cross-links. Essays Biochem 2019; 63: 349-364.
13. Subramanian M, Hunt AL, Petrucci GA, Chen Z, Hendley ED, Palmer BM. Differential metal content and gene expression in rat left ventricular hypertrophy due to hypertension and hyperactivity. J Trace Elem Med Biol 2014; 28: 311-316.
14. Nave AH, Mižíková I, Niess G, Steenbock H, Reichenberger F, Talavera ML, et al. Lysyl oxidases play a causal role in vascular remodeling in clinical and experimental pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 2014; 34: 1446-1458.
15. Yang J, Savvativs K, Kang JS, Fan P, Zhong H, Schwartz K, et al. Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment. Nat Commun 2016; 7: 13710.
16. Zhao Y, Tang K, Tianbao X, Wang J, Yang J, Li D. Increased serum lysyl oxidase-like 2 levels correlate with the degree of left atrial fibrosis in patients with atrial fibrillation. Biosci Rep 2017; 37: BSR20171332.
17. Ba B, Mayila A, Guo Y, Xu J, Xing S, Cao G. NLRC5 enhances autophagy via inactivation of AKT/mTOR pathway and ameliorates cardiac hypertrophy. Int J Exp Pathol 2022; 103: 23-30.
18. Hong X, Yu JJ. Silencing of lysyl oxidase‑like 2 inhibits the migration, invasion and epithelial‑to‑mesenchymal transition of renal cell carcinoma cells through the Src/FAK signaling pathway. Int J Oncol 2019; 54: 1676-1690.
19. Cheng H, Li J, Wu Q, Zheng X, Gao Y, Yang Q, Sun N, He M, Zhou Y. Effect of SKF‑96365 on cardiomyocyte hypertrophy induced by angiotensin II. Mol Med Rep 2020; 21: 806-814.
20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408.
21. Galán M, Varona S, Guadall A, Orriols M, Navas M, Aguiló S, et al. Lysyl oxidase overexpression accelerates cardiac remodeling and aggravates angiotensin II-induced hypertrophy. FASEB J 2017; 31: 3787-3799.
22. Ohmura H, Yasukawa H, Minami T, Sugi Y, Oba T, Nagata T, et al. Cardiomyocyte-specific transgenic expression of lysyl oxidase-like protein-1 induces cardiac hypertrophy in mice. Hypertens Res 2012; 35: 1063-1068.
23. Blom JN, Feng Q. Cardiac repair by epicardial EMT: Current targets and a potential role for the primary cilium. Pharmacol Ther 2018; 186: 114-129.
24. Bagchi RA, Roche P, Aroutiounova N, Espira L, Abrenica B, Schweitzer R, et al. The transcription factor scleraxis is a critical regulator of cardiac fibroblast phenotype. BMC Biol 2016; 14: 21-41.
25. Dixon IMC, Landry NM, Rattan SG. Periostin reexpression in heart disease contributes to cardiac interstitial remodeling by supporting the cardiac myofibroblast phenotype. Adv Exp Med Biol 2019; 1132: 35-41.
26. Xie P, Yu H, Wang F, Yan F, He X. Inhibition of LOXL2 enhances the radiosensitivity of castration-resistant prostate cancer cells associated with the reversal of the EMT process. Biomed Res Int 2019; 2019: 4012590.
27. Hong X, Yu JJ. Silencing of lysyl oxidase‑like 2 inhibits the migration, invasion, and epithelial‑to‑mesenchymal transition of renal cell carcinoma cells through the Src/FAK signaling pathway. Int J Oncol 2019; 54: 1676-1690.
28. Tsubakihara Y, Moustakas A. Epithelial-mesenchymal transition and metastasis under the control of transforming growth factor β. Int J Mol Sci 2018; 19: 3672-3701.
29. Yue Y, Meng K, Pu Y, Zhang X. Transforming growth factor beta (TGF-β)  mediates cardiac fibrosis and induces diabetic cardiomyopathy. Diabetes Res Clin Pract 2017; 133: 124-130.
30. Heger J, Schulz R, Euler G. Molecular switches under TGFβ signaling during progression from cardiac hypertrophy to heart failure. Br J Pharmacol 2016; 173: 3-14.
31. Chen T, Li J, Liu J, Li N, Wang S, Liu H, et al. Activation of SIRT3 by resveratrol ameliorates cardiac fibrosis and improves cardiac function via the TGF-β/Smad3 pathway. Am J Physiol Heart Circ Physiol 2015; 308: 424-434.
32. Lu J, Shi J, Li M, Gui B, Fu R, Yao G, et al. Activation of AMPK by metformin inhibits TGF-β-induced collagen production in mouse renal fibroblasts. Life Sci 2015; 127: 59-65.
33. Wen X, Liu Y, Bai Y, Li M, Fu Q, Zheng Y. LOXL2, a copper-dependent monoamine oxidase, activates lung fibroblasts through the TGF-β/Smad pathway. Int J Mol Med 2018; 42: 3530-3541.
34. de Jong OG, van der Waals LM, Kools FRW, Verhaar MC, van Balkom BMW. Lysyl oxidase-like 2 is a regulator of angiogenesis through modulation of endothelial-to-mesenchymal transition. J Cell Physiol 2019; 234: 10260-10269.
35. Alshenibr W, Tashkandi MM, Alsaqer SF, Alkheriji Y, Wise A, Fulzele S, et al. Anabolic role of lysyl oxidase like-2 in the cartilage of the knee and temporomandibular joints with osteoarthritis. Arthritis Res Ther 2017; 19: 179-193.
36. Xu XH, Jia Y, Zhou X, Xie D, Huang X, Jia L, et al. Downregulation of lysyl oxidase and lysyl oxidase-like protein 2 suppressed the migration and invasion of trophoblasts by activating the TGF-β/collagen pathway in preeclampsia. Exp Mol Med 2019; 51: 1-12.